BioSphere Medical Names Melodie R. Domurad, Ph.D., Vice President of Regulatory, Medical Affairs, and Quality Systems

BioSphere Medical, Inc. (NASDAQ: BSMD) ("BioSphere”), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors, and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy, today announced that Melodie R. Domurad, Ph.D. has joined BioSphere as Vice President of Regulatory, Medical Affairs, and Quality Systems, a newly created position. Ms. Domurad will report to Richard Faleschini, BioSphere’s President and Chief Executive Officer. Domurad joins BioSphere after ten years at Matritech, Inc., a leading developer of proteomics-based diagnostic products for the early detection of cancer. She served as the company’s Vice President, Clinical, Regulatory & Quality Affairs, reporting to the President. While at Matritech, Domurad developed and implemented programs that produced the first FDA-approved laboratory-based test for the initial diagnosis of bladder cancer, and the first and only FDA-approved point-of-care diagnostic for the initial detection of bladder cancer. She managed all of Matritech’s clinical operations in the United States and Europe, served as primary medical liaison with investigators and medical advisors, and oversaw all Quality Assurance activities. Domurad began her career at the company as Matritech’s Director of Clinical Research and later as Director of Clinical and Regulatory Affairs. Prior to Matritech, Domurad was Director of Clinical Research and Clinical Research Manager at Ergo Science, Inc., where she focused on therapeutics for diabetes, obesity, and cancer. In these roles, she assembled and managed research teams, represented the company to the FDA and corporate partners, authored all clinical materials for NDA submissions, and handled Quality Assurance audits. Her prior experience includes leadership roles at the Center for the Study of Nutrition and Medicine at New England Deaconess Hospital, and Cambridge Center for Holistic Health. Domurad received a BA from Cornell University and a Ph.D. from the University of Cincinnati. Richard Faleschini, President and Chief Executive Officer of BioSphere Medical, commented, "BioSphere’s worldwide growth in the areas of interventional gynecology and interventional oncology has been driven by our ability to leverage our embolic technology platform to create and market minimally invasive, innovative, and effective therapies. Melodie’s impressive background, experience, and accomplishments will make her a tremendous asset to BioSphere as we continue to commercialize both our own intellectual property and new product concepts, as well as those that result from our recently announced strategic collaboration with the Applied BioSciences group at DuPont.” About BioSphere Medical, Inc. BioSphere Medical, Inc., a medical device company based in Rockland, Massachusetts, seeks to develop and commercialize minimally invasive diagnostic and therapeutic applications based upon its pioneering proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties that are designed for a variety of medical applications. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure as well as in a number of other new and established medical treatments. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For a discussion of important risks and uncertainties which could cause actual results to differ from those contained in such forward-looking statements, see "Risk Factors" in BioSphere’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2007, as filed by the Company with the Securities and Exchange Commission, and described in other filings made by the Company from time to time with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date of this press release and the Company disclaims any obligation to update these forward-looking statements as a result of changed events, circumstances or otherwise.